Shares of BKV Corp—a unit of Thailand’s billionaire Vongkusolkit family's Banpu—closed flat in its trading debut on Thursday ...

Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears ...

Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price. BioAge (BIOA) stock ...

BKV shares rose by 3.1% on their New York Stock Exchange debut on Thursday. This gives the U.S. Natural Gas Producer a market cap of $1.56 Billion.

(Reuters) -Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

Natural gas producer BKV Corp said on Wednesday it had raised $270 million in its U.S. initial public offering.

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

BKV Corp. priced its common shares at $18 each after and will begin trading on Sept. 26, about two years after the Denver ...

BKV Corporation BKV IPO will take place September, 26 on the NYSE exchange under the ticker BKV. The company is offering shares at an expected price between $19.00 and $21.00 per share with an insider ...

The Dallas-based company focuses on so-called outparcels, properties that point directly onto high-traffic roads that are visible to consumers, and Illinois is its largest market.